Norlichexanthone purified from plant endophyte prevents postmenopausal osteoporosis by targeting ER

Author: Keqi WANG ¹ ; Yongyan CHEN ¹ ; Shuo GAO ¹ ; Maosi WANG ¹ ; Mengmeng GE ¹ ; Qian YANG ¹ ; Mingkai LIAO ¹ ; Lin XU ¹ ; Junjie CHEN ¹ ; Zhiping ZENG ¹ ; Haifeng CHEN ¹ ; Xiao-Kun ZHANG ¹ ; Ting LIN ¹ ; Hu ZHOU ¹
Author Information

1. School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen 361102, China.
Publication Type:Journal Article
Keywords: ERα; Norlichexanthone; Osteoclast; Osteoporosis; RANKL signaling; TRAF6
From: Acta Pharmaceutica Sinica B 2021;11(2):442-455
CountryChina
Language:English
Abstract: Although different types of drugs are available for postmenopausal osteoporosis, the limitations of the current therapies including drug resistances and adverse effects require identification of novel anti-osteoporosis agents. Here, we defined that norlichexanthone (NOR), a natural product, is a ligand of estrogen receptor-alpha (ER